课题基金 / 基金详情

Co-culture cassette for anaerobes and primary human intestinal epithelium

Co-culture cassette for anaerobes and primary human intestinal epithelium
厌氧菌和原代人肠上皮共培养盒
批准号:
10018032
负责人:
Christopher Eldridge Sims
金额:
$74.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-21 至 2021-12-31

项目摘要

项目成果

Christopher Eldridge Sims的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary The human colon is a remarkable organ, playing critical roles in drug uptake and metabolism as well as harboring the 100 trillion microbial cells of the microbiome, which itself has multiple impacts on human health. For these reasons, there is a widespread need in academia and the biotechnology marketplace for in vitro studies of human colon physiology and the interaction between colon tissue and the anaerobic bacteria of the microbiome. To meet this need, Altis Biosystems, Inc., an early stage biotechnology company, has collaborated with scientists at the University of North Carolina (UNC) at Chapel Hill to develop a new platform for cell culture to co-culture normal, human colonic epithelial cells with anaerobic microbiota, named the Self-sustaining Intestinal Microbiome Platform (SIMPle). SIMPle is an easy-to-use and intuitive platform to replicate the steep oxygen gradient across the in vivo colonic epithelium, thus create the appropriate environment required for anaerobes while maintaining viable, healthy epithelial tissue. We have finished the SBIR Phase I program by designing, prototyping, validating the SIMPLe that fits a standard 12-well plate (SIMPle12). The generation of a steep O2 gradient was confirmed, and its impact on cells was characterized. The co-culture of facultative anaerobes with human colonic epithelium in SIMPle12 platforms was validated. All proposed milestones in the Phase I SBIR were accomplished, thus providing a solid foundation for this Phase II SBIR application. The focus of this Phase II proposal is to scale up SIMPLe platform to a 96-well format (SIMPle96) to meet the market needs for screening assays. The SIMPle96 platform will be prototyped and validated, and human colonic epithelium and co-culture with obligate anaerobes will be characterized. Use SIMPle96 platform for screening probiotics will be demonstrated. An external validation of the platform will be performed to demonstrate its utility in microbe-intestinal assays. The SIMPle co-culture platforms are expected to revolutionize microbiome research by enabling the function of host-microbe interactions to be interrogated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation
  • 批准号:
    10483348
  • 项目类别:
  • 资助金额:
    $99.23万
  • 财政年份:
    2022
  • 负责人:
    Christopher Eldridge Sims
  • 依托单位:
A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing
  • 批准号:
    10482521
  • 项目类别:
  • 资助金额:
    $29.4万
  • 财政年份:
    2022
  • 负责人:
    Christopher Eldridge Sims
  • 依托单位:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
  • 批准号:
    10482465
  • 项目类别:
  • 资助金额:
    $25.66万
  • 财政年份:
    2022
  • 负责人:
    Christopher Eldridge Sims
  • 依托单位:
InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation
  • 批准号:
    10616555
  • 项目类别:
  • 资助金额:
    $98.84万
  • 财政年份:
    2022
  • 负责人:
    Christopher Eldridge Sims
  • 依托单位:
海外基金